Truly Translational Sweden AB was founded in 2011 by former AstraZeneca employees with altogether more than 50 years experience from the Life Science sector, with an emphasis on bringing projects from in vitro studies and animal models into concept testing in patients.
Our experiences span from pre-clinical research to early clinical drug discovery, pharmaceutical and biotech companies as well as both small molecules and biologicals. We have experience from project management, international environment, cross-functional teams and line management.
Our main expertise is in inflammatory diseases, and we have experiences from several therapeutic areas, including Respiratory, Cardiovascular, Oncology, Gastrointestinal and Autoimmunity.
Charlott Brunmark, Ph. D. CSO
Charlott has a strong scientific expertise within in vivo pharmacology and pharmaceutical development of small molecules as well as biologics. She has a Ph. D. in Medical Sciences from Lund University whereafter she worked for two years as a visiting scientist at Harvard Medical School in Boston. Charlott has a long experience from the pharmaceutical industry working in both large pharma and small Biotech companies (Pharmacia Upjohn, Active Biotech, Cartela and AstraZeneca). During these years Charlott’s work has been focused on inflammation, autoimmunity and respiratory diseases. In this work translational science i.e. linking effect to exposure and pre-clinical readouts to man has been a key focus. Since 2011 she is the CSO and co-founder of Truly Translational Sweden AB.
Karin von Wachenfeldt, Ph. D. CEO
Karin has a strong scientific expertise in Pharmaceutical development of large and small molecules. She obtained her Ph. D from Dept. of Immunotechnology at Lund University. Karin has over 20 years experience from the pharmaceutical industry (BioInvent, Ixsys Inc. PharmaciaUpjohn, Active Biotech and AstraZeneca) developing drugs for cancer and Respiratory/Inflammation. At AstraZeneca R&D Lund Karin was instrumental in the implementation of translational science and biomarker strategies within the discovery projects, and worked closely with the early clinical organization. Since 2011 she is the CEO and co-founder of Truly Translational Sweden AB. To prepare for this new challenge she has complemented her scientific training and experience with a degree in marketing and leadership.
Åsa Sjöholm Timén, Ph.D. , Business Development Director
Åsa has many years of experience of business development and research in pharma and biotech companies. She has a solid scientific background with a Ph.D. in organic chemistry from Royal Institute of Technology, Stockholm, and hands-on experience of discovery research in the pharmaceutical industry. Åsa joined Astra (later AstraZeneca) in 1996 where she held different positions in Discovery and in the Strategic Partnering Business Development function. In 2010 she joined Spago Imaging (later Spago Nanomedical) as Director Business Development and member of the leadership team. As a result, Åsa has broad experience of corporate business development activities, strategic alliances, and global deal-making covering discovery through early clinical stage opportunities and studies, in biotech and pharma companies. Since 2015 she is the Business Development Director at Truly Translational Sweden AB.